MG MED Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
3,875
4,691
5,387
5,098
4,670
Cost of Goods Sold (COGS) incl. D&A
2,558
2,757
2,694
3,155
4,014
Gross Income
1,317
1,933
2,693
1,943
657
SG&A Expense
1,266
1,524
2,092
2,557
3,814
EBIT
25
373
561
682
3,254
Non Operating Income/Expense
57
212
3
1
29
Interest Expense
250
-
-
-
169
Pretax Income
220
225
628
435
3,182
Income Tax
36
17
12
45
1,003
Consolidated Net Income
255
208
615
480
2,178
Net Income
255
208
615
480
2,178
Net Income After Extraordinaries
255
208
615
480
2,178
Net Income Available to Common
255
208
615
480
2,178
EPS (Basic)
16.41
13.37
46.67
30.13
121.67
Basic Shares Outstanding
16
16
13
16
18
EPS (Diluted)
16.41
13.37
38.37
25.94
121.73
Diluted Shares Outstanding
16
16
16
18
18
EBITDA
277
650
879
345
2,733
Other Operating Expense
26
36
40
68
97
Non-Operating Interest Income
56
42
56
232
252

About MG MED

View Profile
Address
Unit 1003, Elysia Building
Seoul SL 08511
Korea, Republic Of
Employees -
Website http://www.cancerrop.com
Updated 09/14/2018
Cancer Rop Co., Ltd. engages in the development of molecular diagnostic products. It operates through Molecular Diagnostics and Bio-Reagents Business divisions. The molecular diagnostic business division provides deoxyribonucleic acid (DNA) chips and polymerase chain reaction(PCR) kits.